LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.83 4.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.52

Max

28.44

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelnas, tenkantis vienai akcijai

-1.01

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-3.2M

-66M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+110.92% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

217M

1.7B

Ankstesnė atidarymo kaina

23.56

Ankstesnė uždarymo kaina

27.83

Naujienos nuotaikos

By Acuity

50%

50%

162 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-03 23:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025-12-03 23:14; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025-12-03 22:01; UTC

Pagrindinės rinkos jėgos

Costco Wholesale Reports Higher Monthly Sales

2025-12-03 21:38; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025-12-03 23:59; UTC

Rinkos pokalbiai

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025-12-03 23:13; UTC

Rinkos pokalbiai

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025-12-03 23:10; UTC

Uždarbis

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025-12-03 23:08; UTC

Rinkos pokalbiai

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025-12-03 23:06; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025-12-03 22:59; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5M

2025-12-03 22:45; UTC

Rinkos pokalbiai

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025-12-03 22:20; UTC

Uždarbis

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025-12-03 22:19; UTC

Uždarbis

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025-12-03 22:17; UTC

Uždarbis

Salesforce Working to Add Voice to Agentforce, CEO Says

2025-12-03 22:16; UTC

Uždarbis

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025-12-03 22:15; UTC

Uždarbis

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025-12-03 22:10; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025-12-03 22:09; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025-12-03 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-03 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-03 21:49; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:23; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025-12-03 21:19; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:06; UTC

Uždarbis

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025-12-03 21:04; UTC

Uždarbis

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025-12-03 21:04; UTC

Uždarbis

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025-12-03 21:03; UTC

Uždarbis

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

110.92% į viršų

12 mėnesių prognozė

Vidutinis 54.67 USD  110.92%

Aukščiausias 90 USD

Žemiausias 21 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

162 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat